Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

653
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
653
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transfusion-related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the MINT trial.

Transfusion·2025
Same author

Association between body mass index and clinical outcomes in patients with acute myocardial infarction and reduced systolic function: Analysis of PARADISE-MI trial data.

European journal of heart failure·2024
Same author

Assessment of smoking care by stroke specialists in patients with recent TIA and minor stroke: an international prospective registry-based cohort study.

BMJ open·2024
Same author

Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States.

Journal of the American Heart Association·2023
Same author

Prevalence and impact of recreational drug use in patients with acute cardiovascular events.

Heart (British Cardiac Society)·2023
Same author

Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study.

Archives of cardiovascular diseases·2022
Same journal

[Advances and perspectives in vascularized composite allotransplantation preservation].

Bulletin de l'Academie nationale de medecine·2025
Same journal

[COVID-19: Neurological manifestations and complications during the acute phase of the disease].

Bulletin de l'Academie nationale de medecine·2024
Same journal

[Role of psychological factors in post-COVID-19 condition].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[From the origin of Sars-CoV-2 to dangerous virology/biology].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Neurological forms of long COVID in adults: Critical approach].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Post-COVID-19 syndrome].

Bulletin de l'Academie nationale de medecine·2023
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

[Antiplatelet agents].

Gabriel Steg

    Bulletin De L'Academie Nationale De Medecine
    |June 13, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Atherothrombosis, a global health issue, involves platelets in disease and thrombosis. Antiplatelet therapies show benefits for preventing recurrent cardiovascular events, especially dual therapy for acute coronary syndromes.

    More Related Videos

    Microfluidics in Assessing Platelet Function
    06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024

    1.7K
    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
    09:13

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

    Published on: April 6, 2017

    11.3K

    Related Experiment Videos

    Last Updated: Apr 28, 2026

    Ferric Chloride-induced Murine Thrombosis Models
    10:37

    Ferric Chloride-induced Murine Thrombosis Models

    Published on: September 5, 2016

    21.9K
    Microfluidics in Assessing Platelet Function
    06:47

    Microfluidics in Assessing Platelet Function

    Published on: November 8, 2024

    1.7K
    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
    09:13

    Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

    Published on: April 6, 2017

    11.3K

    Area of Science:

    • Cardiovascular Medicine
    • Hematology
    • Pharmacology

    Context:

    • Atherothrombosis is a significant global health concern.
    • Chronic atherosclerotic disease can be asymptomatic but lead to severe thrombotic events.
    • Platelets are central to both the development of atherosclerosis and thrombotic complications.

    Purpose:

    • To review the role of antiplatelet agents in managing atherothrombosis.
    • To discuss the efficacy of single and dual antiplatelet therapy for primary and secondary prevention.
    • To evaluate current standards of care and emerging antiplatelet drugs.

    Summary:

    • Antiplatelet therapy, including dual therapy with aspirin and agents like clopidogrel, ticagrelor, or prasugrel, is standard for acute coronary syndromes.
    • Evidence for dual antiplatelet therapy in chronic stable coronary disease is not yet established.
    • Routine antiplatelet use for primary prevention is recommended only for select high-risk individuals, balancing bleeding risk.

    Impact:

    • Informs clinical practice regarding the appropriate use of antiplatelet agents in various atherothrombotic scenarios.
    • Highlights the need for personalized risk assessment in primary prevention strategies.
    • Guides the development and application of new antiplatelet therapies for cardiovascular and cerebrovascular protection.